Novo Nordisk accelerates clinical documentation and drug development with Claude
Novo NordiskClaude Code · Amazon Bedrock · MongoDB AtlasNovo Nordisk, a global pharmaceutical company headquartered in Europe, built NovoScribe, an AI-powered documentation platform using Claude Code, Amazon Bedrock and MongoDB Atlas, to automate clinical study report (CSR) generation. Claude helped cut writing times on CSRs by 90%, reducing time spent producing clinical study documentation from 10+ weeks to 10 minutes, and delivered a 95% reduction in resources needed to create device verification protocols. The platform expanded from clinical trial reports to device protocol documentation and patient materials, and an 11-person development team, including non-technical staff, now prototypes features using Claude Code.
Overview
Novo Nordisk, a global pharmaceutical company headquartered in Europe, built NovoScribe, an AI-powered documentation platform using Claude Code, Amazon Bedrock and MongoDB Atlas, to automate clinical study report (CSR) generation. Claude helped cut writing times on CSRs by 90%, reducing time spent producing clinical study documentation from 10+ weeks to 10 minutes, and delivered a 95% reduction in resources needed to create device verification protocols. The platform expanded from clinical trial reports to device protocol documentation and patient materials, and an 11-person development team, including non-technical staff, now prototypes features using Claude Code.
This entry has 15 published fields tied to exact passages in an immutable source capture.
Inspect the highlighted sourceThe challenge
For pharmaceutical companies, the path from drug discovery to patient access is paved with paperwork. Producing the documentation for a clinical trial consumed so much time and so many resources, even with help from external agencies, that it was slowing down the organization's ability to bring new medicines to market. Staff writers averaged only 2.3 CSRs per year, and the manual process remained prone to errors and subjective interpretation.
The solution
Novo Nordisk used Claude Code to develop NovoScribe, a generative AI documentation platform built on Amazon Bedrock and MongoDB Atlas, with Claude models as the frontier intelligence driving the entire system. The platform combines retrieval-augmented generation (RAG) with domain expert-approved text and case-specific variables to produce accurate, compliant documentation. Initially the team focused on perfecting NovoScribe for clinical study report (CSR) production, then expanded to device protocol documentation and patient materials.
Reported business value
Claude has helped Novo Nordisk cut writing times on clinical study reports (CSRs) by 90%. Time spent producing clinical study documentation was reduced from 10+ weeks to 10 minutes, and device verification protocols saw a 95% reduction in resources needed. For new trials, the team can now produce a complete study booklet and patient guide in under a minute.
Sources
Open any source and check the claim yourself — that is the point of the register.
This record was researched and written with AI assistance, and its claims were checked against the sources above. (EU AI Act art. 50 transparency notice.)
Other life sciences entries in the register.
Protecting Crops Today to Feed Billions Tomorrow
Syngenta built Gaia, the first crop protection R&D data platform for analytics and innovation, on Databricks to unify siloed data across 70-plus countries. The platform cut data access times from as long as nine months to minutes, reduced time to value by 70%, decreased engineering costs by 50%, and now publishes over 200 data products handling more than 2 million queries per month.
SyngentaDatabricks · Delta Lake · Unity Catalog +3
Novartis: Accelerating Drug Development with AI-Powered Clinical Trial Transformation
Novartis partnered with AWS Professional Services and Accenture to modernize their drug development infrastructure and integrate AI across clinical trials, with the goal of reducing trial development cycles by at least six months. The initiative built a GXP-compliant data mesh platform on AWS with Databricks for processing, enabling AI use cases including protocol generation and an intelligent decision system (digital twin). Early results from the patient safety domain showed 72% query speed improvements, 60% storage cost reduction, and 160+ hours of manual work eliminated. The protocol generation use case achieved 83-87% acceleration in producing compliant protocols.
NovartisAmazon Web Services (AWS) · Databricks · Amazon S3 +8
Phagos uses generative AI on AWS to match bacteriophages to bacterial infections
Phagos, a Paris-based biotech startup, uses generative AI models built with Amazon SageMaker AI to match bacteriophages to target bacteria for phage therapy, replacing a manual trial-and-error process. The AI models cut wet-lab testing needs by 50% and reduced phage-candidate screening time by 99.5%, from 29 hours to 10 minutes per bacteria. Phagos has treated more than half a million animals in France and can now develop a new treatment in two months versus 10+ years for traditional antibiotic development.
Phagos· FranceAmazon SageMaker AI · Amazon EC2 · Amazon S3 +1Was this helpful?
Your feedback helps us improve our use case database